Inhibrx Biosciences: Bank of America reports 2.4% stake
The reported 2.4% position carries shared voting power over 357,306 shares and shared dispositive power over 357,318 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Inhibrx Biosciences, Inc. common stock was the subject of an amended ownership report by Bank of America Corporation and its wholly owned subsidiaries, which reported beneficial ownership of 357,318 shares, or 2.4% of the class. The group reported shared voting power over 357,306 shares and shared dispositive power over 357,318 shares, with no sole voting or dispositive power. The ownership calculation used 14,717,660 shares outstanding as of August 7, 2026, as disclosed in the issuer’s Form 10-Q.
Key Figures
Key Terms
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.